PCV-13
PreclinicalBiologic
PCV-13 is one of 22 biologic programs targeting Immune Response. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Immune Response
#DrugCompanyPhaseTrials
1Influenza Vaccine
NovartisPhase 3
Recombinant Zoster Vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
Xylocaine
MMEDRx USA, Inc.
Phase 2
Flumist
AstraZenecaPhase 3
Decadron
AAspen Global Incorporated
Phase 2
INMAZEB
RegeneronPhase 2
Rmenb+omv
NovartisPhase 3
Immunonutrition
SSt. Antonius Hospital
Phase 3
Ervebo
AANRS, Emerging Infectious Diseases
Phase 2
Rabies Vaccine
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PCV-13. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Colorado, Denver